Zura Bio (ZURA) Cash & Equivalents (2021 - 2026)

Zura Bio's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $225.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 32.24% year-over-year to $225.6 million in Q1 2026; TTM through Mar 2026 was $225.6 million, a 32.24% increase from a year earlier, with the FY2025 full-year figure at $109.4 million, down 35.91% from the prior year.
• Cash & Equivalents rose to $225.6 million in Q1 2026 per ZURA's latest filing, from $109.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $225.6 million in Q1 2026 and bottomed at $1.6 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $109.4 million (2025), against an average of $106.5 million.
• Across the five-year window, Cash & Equivalents jumped 6269.24% in 2023 and tumbled 35.91% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $1.6 million in 2022, then soared by 6269.24% to $99.8 million in 2023, then jumped by 71.03% to $170.7 million in 2024, then tumbled by 35.91% to $109.4 million in 2025, then jumped by 106.2% to $225.6 million in 2026.
• Per Business Quant, the three latest ZURA Cash & Equivalents figures stand at $225.6 million (Q1 2026), $109.4 million (Q4 2025), and $139.0 million (Q3 2025).